Navigation Links
Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
Date:4/1/2008

- Company Believes That Continuing to Follow Dispute Resolution Process is

the Most Expeditious Path to Final Approval -

LAVAL, QC, April 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has appealed the U.S. Food and Drug Administration's (FDA) decision on its once-daily tramadol formulation to the next supervisory level under the FDA's Formal Dispute Resolution process. Labopharm's continuation of the appeal process follows the completion of additional statistical analysis of existing data per the suggestion of Dr. John K. Jenkins, M.D., the FDA's Director for the Office of New Drugs, Center for Drug Evaluation and Research, as a means to potentially satisfy the FDA's requirements for regulatory approval. The Company believes that the additional analysis confirms the conclusions of efficacy of its once-daily tramadol formulation as demonstrated in previous analyses that were included in its New Drug Application (NDA) and additional submissions thereafter.

"We have maintained the position that our strong body of data warrants the approval of our once-daily tramadol formulation and believe that the additional analysis we conducted as proposed by the FDA confirms our position," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We believe that continuing the Formal Dispute Resolution process, as opposed to submitting a complete response, is the most appropriate path to resolving the outstanding matter and achieving our objective of commercialization in the United States."

As part of the appeal process, Labopharm has requested a meeting with Dr. Janet Woodcock, M.D., the FDA's Director, Center for Drug Evaluation and Research. The Agency usually grants such requests within 30 days and typically provides a written response to the appellant within 30 days of a meeting.

About the FDA's Formal Dispute Resolution Process

FDA regulations provide
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
2. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
3. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
4. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
5. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
6. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
7. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
8. Labopharm Reports Results for Third Quarter Fiscal 2007
9. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
10. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
11. Labopharm appeals FDAs decision on once-daily tramadol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Explorys, the ... additions to its leadership team: Greg Yarrington as Vice ... Engineering, and Patrick Wells as Vice President of Solutions. ... add 80 new jobs in 2015 to support client ... of its platform-as-a-service offerings, and growth of its partner ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Xarelto ... federal panel of judges has granted a request to ... the U.S. District Court, Eastern District of Louisiana. The ... order on December 12 to transfer over 50 Xarelto ... districts to the Louisiana court for consolidation under U.S. ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... Boys are twice as,likely as girls in the ... hormone (rhGH) for growth hormone deficiency, illnesses that,affect height, ... gender,difference exists in Europe, Australia and New Zealand, but ... are treated at the same rate. This indicates,a likely ...
... Spanish . , A group of scientists from the ... of the University of Granada have found out ... to obtain inhibitors of neurogenic vasodilatation, a significant progress in migraine ... del Mar Herrador and Alejandro Fernndez Barrero , has ...
... obstetrical data management system integrates system, reliability, improves ... initiatives to help drive improved ... ... 17 Hill-Rom (NYSE:,HRC) today announced the release of an ...
... LIVINGSTON, N.J., April 17 MM2 Group, Inc.,(OTC ... Genotec Nutritionals, Inc., a New York based nutraceutical,company ... its branded,products and through custom formulations for several ... for the manufacture of,fish oil sofgels. The sofgels ...
... approach that combines comprehensive gene expression profiling with genome-wide ... to an important genetic marker that can help physicians ... and will require more aggressive treatment, a research team ... in the April 15, 2008, issue of the journal ...
... Activity, DALLAS, April 17 ACCESS ... from preclinical studies,ongoing at the prestigious Imperial ... antibody. The new data, presented by Dr.,Mahendra ... that Angiolix has unusually high accumulation in ...
Cached Medicine News:Health News:Growth Hormone is Used to Treat Twice as Many Short Boys Than Girls in the U.S. and Asia; Gender Difference is Smaller in the Rest of the World 2Health News:Growth Hormone is Used to Treat Twice as Many Short Boys Than Girls in the U.S. and Asia; Gender Difference is Smaller in the Rest of the World 3Health News:Growth Hormone is Used to Treat Twice as Many Short Boys Than Girls in the U.S. and Asia; Gender Difference is Smaller in the Rest of the World 4Health News:Scientists obtain anticancer medicines from the elecampe, a wild plant growing in the Mediterranean 2Health News:Hill-Rom's NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care 2Health News:MM2 Group Provides Additional Quotes for New Venture in China 2Health News:Genome analysis reveals new protein associated with breast cancer progression 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 2Health News:Access Pharmaceuticals Announces New Data on Angiolix(R) 3
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
(Date:12/19/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ADMD), ... the development of brachytherapy devices and medical isotopes ... a Life Sciences Discovery Fund (LSDF) Proof of ... is the commercialization partner.  The award was made ... titled "Optimized Injectable Radiogels for High-dose Therapy of ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... that Induction Chemotherapy prior to ChemoRadiotherapy significantly ... ChemoRadiotherapy alone -MADRID, May 30 The ... (TTCC) announced today that Induction Chemotherapy (IC) ... treatment paradigm defined as sequential therapy, compared ...
... Fla. , May 29 GlaxoSmithKline [NYSE: ... that the United States Food and Drug Administration,s ... to three that the ARZERRA(TM) (ofatumumab) data are ... with chronic lymphocytic leukemia (CLL) whose disease is ...
Cached Medicine Technology:Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 2Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 2FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 4FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 5
... Thyroid-stimulating hormone (TSH) is a 32 kDa ... the anterior pituitary gland [1]. The structure ... of the pituitary and placental gonadotropins, consisting ... identical between these hormones and a unique ...
... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
Medicine Products: